Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentric, Open-label, Non-randomized, Pharmacokinetic and Tolerability Study of Fexinidazole Given as an Oral Single 1200 mg Dose in Participants With Mild and Moderate Hepatic Impairment, and in Matched Participants With Normal Hepatic Function

NCT05607173 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT05607173
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05607173 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentric, Open-label, Non-randomized, Pharmacokinetic and Tolerability Study of Fexinidazole Given as an Oral Single 1200 mg Dose in Participants With Mild and Moderate Hepatic Impairment, and in Matched Participants With Normal Hepatic Function
Lead sponsor
Sanofi
Phase
Phase 1
Overall status
Completed
Start date
January 18, 2023
Completion date
May 3, 2023
Enrollment
21 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic function abnormal